A trial HIV vaccine helps to produce those elusive but crucial antibodies, paving the path for a vaccine that works.

Published Date: 22 May 2024

A small number of individuals participating in a 2019 clinical trial had low levels of an elusive type of broadly neutralizing HIV antibodies in response to an HIV vaccine candidate developed at the Duke Human Vaccine Institute.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot